Sensitivity (+) |
ERBB2 oncogenic variants
|
Non-Small Cell Lung Cancer |
Trastuzumab deruxtecan
|
|
Sensitivity (+) |
ERBB2 amplification
|
Invasive Breast Carcinoma |
Docetaxel,
Trastuzumab
|
|
Sensitivity (+) |
ERBB2 amplification
|
Invasive Breast Carcinoma |
Trastuzumab deruxtecan
|
|
Sensitivity (+) |
ERBB2 amplification
|
Non-Small Cell Lung Cancer |
Trastuzumab deruxtecan
|
|
Sensitivity (+) |
ERBB2 oncogenic variants
|
Non-Small Cell Lung Cancer |
Trastuzumab deruxtecan
|
|
Sensitivity (+) |
ERBB2 amplification
|
Adenocarcinoma of the Gastroesophageal Junction |
Trastuzumab deruxtecan
|
|
Sensitivity (+) |
ERBB2 amplification
|
Invasive Breast Carcinoma |
Trastuzumab
|
|
Sensitivity (+) |
ERBB2 amplification
|
Invasive Breast Carcinoma |
Paclitaxel,
Trastuzumab
|
|
Sensitivity (+) |
ERBB2 amplification
|
Invasive Breast Carcinoma |
Docetaxel,
Trastuzumab
|
|
Sensitivity (+) |
ERBB2 amplification
|
Invasive Breast Carcinoma |
Anastrozole,
Trastuzumab
|
|
Sensitivity (+) |
ERBB2 amplification
|
Invasive Breast Carcinoma |
Trastuzumab
|
|
Sensitivity (+) |
ERBB2 amplification
|
Invasive Breast Carcinoma |
Paclitaxel,
Trastuzumab
|
|
Sensitivity (+) |
ERBB2 amplification
|
Invasive Breast Carcinoma |
Docetaxel,
Trastuzumab
|
|
Sensitivity (+) |
ERBB2 amplification
|
Invasive Breast Carcinoma |
Carboplatin,
Docetaxel,
Trastuzumab
|
|
Sensitivity (+) |
ERBB2 amplification
|
Invasive Breast Carcinoma |
Doxorubicin,
Paclitaxel,
Trastuzumab
|
|
Sensitivity (+) |
ERBB2 amplification
|
Esophagogastric Adenocarcinoma |
Capecitabine,
Cisplatin,
Trastuzumab
|
|
Sensitivity (+) |
ERBB2 amplification
|
Esophagogastric Adenocarcinoma |
Cisplatin,
Fluorouracil,
Trastuzumab
|
|
Sensitivity (+) |
ERBB2 amplification
|
Invasive Breast Carcinoma |
Trastuzumab emtansine
|
|
Sensitivity (+) |
ERBB2 amplification
|
Invasive Breast Carcinoma |
Trastuzumab emtansine
|
|
Sensitivity (+) |
ER positive,
ERBB2 amplification,
PR positive
|
Invasive Breast Carcinoma |
Neratinib
|
|
Sensitivity (+) |
ER positive,
ERBB2 amplification
|
Invasive Breast Carcinoma |
Neratinib
|
|
Sensitivity (+) |
ERBB2 amplification,
PR positive
|
Invasive Breast Carcinoma |
Neratinib
|
|
Sensitivity (+) |
ERBB2 amplification
|
Invasive Breast Carcinoma |
Capecitabine,
Lapatinib
|
|
Sensitivity (+) |
ER positive,
ERBB2 amplification,
PR negative
|
Invasive Breast Carcinoma |
Lapatinib,
Trastuzumab
|
|
Sensitivity (+) |
ER positive,
ERBB2 amplification,
PR positive
|
Invasive Breast Carcinoma |
Lapatinib,
Letrozole
|
|